Levine Alexander R, Thanikonda Varshitha, Mueller Jane, Naut Edgar R
Department of Pharmacy Practice, University of Saint Joseph School of Pharmacy & Physician Assistant Studies, Hartford, Connecticut, United States of America; Clinical Pharmacist, Department of Pharmacy, Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States of America.
UConn Health, Farmington, Connecticut, United States of America.
Am J Emerg Med. 2021 Jun;44:415-418. doi: 10.1016/j.ajem.2020.04.095. Epub 2020 May 4.
Front-loaded diazepam is used to rapidly control agitation in patients with severe alcohol withdrawal syndrome (AWS). Our institution began using front-loaded lorazepam in August 2017 secondary to a nation-wide shortage of intravenous (IV) diazepam. Currently, there are no studies comparing lorazepam to diazepam for frontloading in severe AWS.
Retrospective cohort study of all adults presenting to the emergency department with a diagnosis of AWS and prescribed the institution's alcohol withdrawal agitated delirium protocol 8 months pre and post shortage of IV diazepam were eligible inclusion for the study. Of these, 106 patients were front-loaded with diazepam and 70 patients were front-loaded with lorazepam.
There was no difference in the mean change in Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised scores 24 h pre and post front-loading in the two groups (-13.9 ± -8.08 vs. -13.1 ± -8.91, p = 0.534). Patients who received front-loaded lorazepam had an increased incidence of ICU-delirium (positive for the Confusion Assessment Method in the ICU: 75% with lorazepam vs. 52.6% with diazepam, p = 0.009) and a higher risk of over-sedation, but this did not reach statistical significance (Richmond Agitation-Sedation Scale score < -1: 32.1% with lorazepam vs. 18.2% with diazepam, p = 0.063).
Front-loaded lorazepam was similar to front-loaded diazepam in controlling AWS symptoms. Lorazepam's delayed onset of action should be considered when determining how quickly repeat doses are administered to avoid the potential for adverse drug events.
预负荷地西泮用于快速控制严重酒精戒断综合征(AWS)患者的激越症状。由于全国范围内静脉用地西泮短缺,我院于2017年8月开始使用预负荷劳拉西泮。目前,尚无关于在严重AWS中预负荷使用劳拉西泮与地西泮对比的研究。
对所有因AWS诊断而就诊于急诊科且在静脉用地西泮短缺前后8个月内按照我院酒精戒断激越谵妄方案用药的成年患者进行回顾性队列研究。其中,106例患者预负荷用地西泮,70例患者预负荷用劳拉西泮。
两组在预负荷前后24小时酒精戒断临床研究所修订评估量表(CIWA-Ar)评分的平均变化无差异(-13.9±-8.08 vs. -13.1±-8.91,p=0.534)。接受预负荷劳拉西泮的患者发生重症监护病房谵妄的发生率增加(重症监护病房意识模糊评估方法阳性:劳拉西泮组为75%,地西泮组为52.6%,p=0.009),且过度镇静风险更高,但未达到统计学意义(里士满激越-镇静量表评分<-1:劳拉西泮组为32.1%,地西泮组为18.2%,p=0.063)。
预负荷劳拉西泮在控制AWS症状方面与预负荷地西泮相似。在确定重复给药速度时应考虑劳拉西泮起效延迟,以避免发生药物不良事件。